This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate
biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to
placebo in patients with severe sepsis at risk for or with acute lung injury. The hypothesis
is that intravenous L-citrulline will decreased the development or progression of acute lung
injury in patients with severe sepsis compared to placebo.